JO2031B1 - 5-(2-ethyl-2h-tetrazol-5-y1)-1-methyl-1,2,3,6-tetrahydropyridine - Google Patents

5-(2-ethyl-2h-tetrazol-5-y1)-1-methyl-1,2,3,6-tetrahydropyridine

Info

Publication number
JO2031B1
JO2031B1 JO19982031A JOP19982031A JO2031B1 JO 2031 B1 JO2031 B1 JO 2031B1 JO 19982031 A JO19982031 A JO 19982031A JO P19982031 A JOP19982031 A JO P19982031A JO 2031 B1 JO2031 B1 JO 2031B1
Authority
JO
Jordan
Prior art keywords
tetrahydropyridine
tetrazol
ethyl
methyl
acid addition
Prior art date
Application number
JO19982031A
Other languages
Arabic (ar)
Inventor
بيك سومير مايكل
نيلسين أولي
Original Assignee
إتش لوندبيك إيه /إس
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by إتش لوندبيك إيه /إس filed Critical إتش لوندبيك إيه /إس
Application granted granted Critical
Publication of JO2031B1 publication Critical patent/JO2031B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to a maleate acid addition salt of 5-(2-ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridine, pharmaceutical compositions containing the acid addition salt and the use thereof for the treatment of disorders caused by a malfunction of the acetylcholine (AcCh) or muscarinic system.
JO19982031A 1997-07-01 1998-06-25 5-(2-ethyl-2h-tetrazol-5-y1)-1-methyl-1,2,3,6-tetrahydropyridine JO2031B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK78197 1997-07-01

Publications (1)

Publication Number Publication Date
JO2031B1 true JO2031B1 (en) 1999-05-15

Family

ID=8097489

Family Applications (1)

Application Number Title Priority Date Filing Date
JO19982031A JO2031B1 (en) 1997-07-01 1998-06-25 5-(2-ethyl-2h-tetrazol-5-y1)-1-methyl-1,2,3,6-tetrahydropyridine

Country Status (25)

Country Link
EP (1) EP0994869A1 (en)
JP (1) JP2002507215A (en)
KR (1) KR20010014297A (en)
CN (1) CN1261361A (en)
AR (1) AR013096A1 (en)
AU (1) AU735751B2 (en)
BG (1) BG103933A (en)
BR (1) BR9810331A (en)
CA (1) CA2293324A1 (en)
CO (1) CO4940483A1 (en)
EA (1) EA200000081A1 (en)
HU (1) HUP0002876A2 (en)
IL (1) IL133093A0 (en)
IS (1) IS5278A (en)
JO (1) JO2031B1 (en)
MA (1) MA25138A1 (en)
NO (1) NO996580D0 (en)
PE (1) PE116099A1 (en)
PL (1) PL337184A1 (en)
SK (1) SK187399A3 (en)
TN (1) TNSN98120A1 (en)
TR (1) TR199903283T2 (en)
UY (2) UY25069A1 (en)
WO (1) WO1999001448A1 (en)
ZA (1) ZA985498B (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8714789D0 (en) * 1987-06-24 1987-07-29 Lundbeck & Co As H Heterocyclic compounds
JPH11514654A (en) * 1995-11-06 1999-12-14 ハー・ルンドベック・アクチェゼルスカベット How to treat brain injury due to trauma

Also Published As

Publication number Publication date
EA200000081A1 (en) 2000-08-28
TNSN98120A1 (en) 2005-03-15
AU8102098A (en) 1999-01-25
PL337184A1 (en) 2000-08-14
HUP0002876A2 (en) 2001-06-28
MA25138A1 (en) 2001-04-02
WO1999001448A1 (en) 1999-01-14
IS5278A (en) 1999-11-30
AR013096A1 (en) 2000-12-13
NO996580L (en) 1999-12-30
UY25069A1 (en) 1998-12-21
ZA985498B (en) 1999-01-20
KR20010014297A (en) 2001-02-26
CO4940483A1 (en) 2000-07-24
SK187399A3 (en) 2000-06-12
NO996580D0 (en) 1999-12-30
BR9810331A (en) 2000-09-05
EP0994869A1 (en) 2000-04-26
TR199903283T2 (en) 2000-06-21
CA2293324A1 (en) 1999-01-14
UY25177A1 (en) 2000-12-29
BG103933A (en) 2000-07-31
IL133093A0 (en) 2001-03-19
CN1261361A (en) 2000-07-26
PE116099A1 (en) 1999-11-23
AU735751B2 (en) 2001-07-12
JP2002507215A (en) 2002-03-05

Similar Documents

Publication Publication Date Title
CA2198238A1 (en) Piperidine derivatives as neurokinin antagonists
EP0896533A4 (en) Pentafluorobenzenesulfonamides and analogs
WO2000047568A3 (en) 1,2-benzothiazepines for the treatment of hyperlipidemic diseases
GEP20043303B (en) Polycycloalkylpurines as Adenosine Receptor Antagonists
BG103297A (en) Aralkyl and aralkyliden heterocyclic lactams and imides
NZ329627A (en) 8-Heterocyclically substituted 1,3,8-triaza-spiro[4.5]decan-4-ones
SI0725779T1 (en)
MX9605741A (en) (r)-(-)-2-{n-[4-(1,1-dioxide-3-oxo-2,3-dihydro-benzisotiazole-2-yl)-buty l]-aminomethyl}-cromane crystalline chlorhydrate.
CA2090220A1 (en) Treatment of non-inflammatory and non-infectious bowel disorders
PL374325A1 (en) Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
HUT71550A (en) Pharmaceutical agents containing quinuclidine, piperidine or azanorbornane derivatives for treatment of emesis
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
DZ2141A1 (en) Intermediate processes for the preparation of 1-benzyl-4- (5,6-dimethoxy-1-indanone) -2-yi) methylpiperidine.
WO2001010408A3 (en) Aqueous pharmaceutical composition containing moxifloxacin or salts thereof
CA2235747A1 (en) Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for preparing drugs for treating amyotrophic lateral sclerosis
WO1999006388A3 (en) Pharmaceutical compounds isolated from aristolochia taliscana
WO1996022305A3 (en) Modified peptides
CA2168131A1 (en) Tetrahydro-1h-benzazepinones containing acid surrogates
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BR9811821A (en) 2-acylaminopropanamines as tachykinin receptor antagonists
WO1996031208A3 (en) Use of substituted piperidine or pyrrolidine compounds for treating sigma-receptor modulated disorders
NZ220195A (en) 2-pyridyl-penem derivatives and pharmaceutical compositions
JO2031B1 (en) 5-(2-ethyl-2h-tetrazol-5-y1)-1-methyl-1,2,3,6-tetrahydropyridine
WO2000033788A3 (en) Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
CA2309439A1 (en) 3-(3-hydroxyphenyl)-3-amino-propionamide derivatives